Multiple high-risk cytogenetic aberrations confer a progressively negative impact on survivals of newly diagnosed myeloma patients

被引：0
|
作者：
Mao, Xuehan [1 ,2 ]
Xu, Yan [3 ]
Yan, Yuting [1 ,2 ]
Liu Jiahui [1 ,2 ]
Fan Huishou [1 ,2 ]
Sui Weiwei [1 ,2 ]
Zengjun, Lizengjun [1 ,2 ]
Deng, Shuhui [4 ,5 ]
Yi, Shuhua [1 ,2 ]
Wang, Tingyu [1 ,2 ]
Wang, Qi [6 ]
Liu, Hui-Min [1 ,2 ]
Qiu, Lugui [1 ,2 ]
An, Gang [1 ,2 ]
机构：
[1] Chinese Acad Med Sci & Peking Union, Inst Hematol, Tianjin, Peoples R China
[2] Chinese Acad Med Sci & Peking Union, Blood Dis Hosp, Tianjin, Peoples R China
[3] Chinese Acad Med Sci, Inst Hematol & Blood Dis, Tianjin, Peoples R China
[4] Chinese Acad Med Sci, Inst Hematol, Tianjin, Peoples R China
[5] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin, Peoples R China
[6] Chinese Acad Med Sci & Peking Union Medi, Iymphoma & Myeloma, Blood Dis Hosp, Tianjin, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2019年 / 19卷 / 10期
关键词：
cytogenetic abnormality; myeloma; survival;
D O I：
10.1016/j.clml.2019.09.132
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
FP-047
引用
收藏
页码：E83 / E83
页数：1
相关论文
共 50 条
  • [21] Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma
    Gonsalves, W. I.
    Rajkumar, S. V.
    Gupta, V.
    Morice, W. G.
    Timm, M. M.
    Singh, P. P.
    Dispenzieri, A.
    Buadi, F. K.
    Lacy, M. Q.
    Kapoor, P.
    Gertz, M. A.
    Kumar, S. K.
    LEUKEMIA, 2014, 28 (10) : 2060 - 2065
  • [22] Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma
    Smallbone, Portia
    Clugston, Stephanie
    De Kraa, Rebecca
    Purtill, Duncan
    Wright, Matthew
    Leahy, Michael F.
    Sidiqi, M. Hasib
    BLOOD, 2020, 136
  • [23] The Impact of Socioeconomic Risk Factors on the Survival Outcomes of Patients with Newly Diagnosed Multiple Myeloma
    Evans, Laura A.
    Go, Ronald S.
    Nandakumar, Bharat
    Buadi, Francis K.
    Dispenzieri, Angela
    Dingli, David
    Lacy, Martha Q.
    Hayman, Suzanne R.
    Kapoor, Prashant
    Leung, Nelson
    Fonder, Amie
    Hobbs, Miriam A.
    Hwa, Yi L.
    Muchtar, Eli
    Warsame, Rahma M.
    Kourelis, Taxiarchis
    Russell, Stephen J.
    Lust, John A.
    Siddiqui, Mustaqeem
    Kyle, Robert A.
    Gertz, Morie A.
    Rajkumar, S. Vincent
    Kumar, Shaji K.
    Gonsalves, Wilson I.
    BLOOD, 2019, 134
  • [24] Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Therapy in High-Risk Newly Diagnosed Multiple Myeloma
    Tan, Carlyn
    Korde, Neha
    Derkach, Andriy
    Hultcrantz, Malin
    Maclachlan, Kylee H.
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi A.
    Rajeeve, Sridevi
    Patel, Dhwani
    Lesokhin, Alexander
    Lahoud, Oscar Boutros
    Shah, Gunjan L.
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio A.
    Hofmeister, Craig C.
    Kaufman, Jonathan L.
    Nooka, Ajay K.
    Usmani, Saad Z.
    Lonial, Sagar
    Joseph, Nisha S.
    BLOOD, 2023, 142
  • [25] Different MAF translocations confer similar prognosis in newly diagnosed multiple myeloma patients
    Goldman-Mazur, Sarah
    Jurczyszyn, Artur
    Castillo, Jorge J.
    Waszczuk-Gajda, Anna
    Grzasko, Norbert
    Radocha, Jakub
    Bittrich, Max
    Kortuem, Klaus Martin
    Gozzetti, Alessandro
    Usnarska-Zubkiewicz, Lidia
    Valls, Julio D.
    Jayabalan, David S.
    Niesvizky, Ruben
    Kelman, Julia
    Coriu, Daniel
    Rosinol, Laura
    Szukalski, Lukasz
    Gonzalez-Calle, Veronica
    Mateos, Maria-Victoria
    Jamroziak, Krzysztof
    Hus, Iwona
    Avivi, Irit
    Cohen, Yael
    Mazur, Piotr
    Suska, Anna
    Chappell, Aimee
    Madduri, Deepu
    Chhabra, Saurabh
    Kleman, Ariel
    Hari, Parameswaran
    Delforge, Michel
    Robak, Pawel
    Gentile, Massimo
    Kozlowska, Izabela
    Goldberg, Stuart L.
    Czepiel, Jacek
    Dlugosz-Danecka, Monika
    Silbermann, Rebecca
    Olszewski, Adam J.
    Barth, Peter
    Mikala, Gabor
    Chim, Chor S.
    Vesole, David H.
    LEUKEMIA & LYMPHOMA, 2020, 61 (08) : 1885 - 1893
  • [26] Impact of Etiological Cytogenetic Abnormalities on the Depth of Immunoparesis and Survival in Newly Diagnosed Multiple Myeloma
    Caro, Jessica
    Cairns, David
    Menzies, Tom
    Boyle, Eileen
    Pawlyn, Charlotte
    Cook, Gordon
    Kaiser, Martin
    Walker, Brian A.
    Owen, Roger
    Jackson, Graham H.
    Morgan, Gareth J.
    Heaney, Jennifer
    Drayson, Mark
    Davies, Faith E.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 (04): : E279 - E284
  • [27] Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
    J R Sawyer
    E Tian
    J D Shaughnessy Jr
    J Epstein
    C M Swanson
    C Stangeby
    C L Hale
    L Parr
    M Lynn
    G Sammartino
    J L Lukacs
    C Stein
    C Bailey
    M Zangari
    F E Davies
    F Van Rhee
    B Barlogie
    G J Morgan
    Leukemia, 2017, 31 : 637 - 644
  • [28] Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma
    Sawyer, J. R.
    Tian, E.
    Shaughnessy, J. D., Jr.
    Epstein, J.
    Swanson, C. M.
    Stangeby, C.
    Hale, C. L.
    Parr, L.
    Lynn, M.
    Sammartino, G.
    Lukacs, J. L.
    Stein, C.
    Bailey, C.
    Zangari, M.
    Davies, F. E.
    Van Rhee, F.
    Barlogie, B.
    Morgan, G. J.
    LEUKEMIA, 2017, 31 (03) : 637 - 644
  • [29] Risk of Early Mortality in Patients With Newly Diagnosed Multiple Myeloma
    Hsu, Pei
    Lin, Ting-Wei
    Gau, Jyh-Pyng
    Yu, Yuan-Bin
    Hsiao, Liang-Tsai
    Tzeng, Cheng-Hwai
    Chen, Po-Min
    Chiou, Tzeon-Jye
    Liu, Jin-Hwang
    Liu, Yao-Chung
    Liu, Chia-Jen
    MEDICINE, 2015, 94 (50)
  • [30] Risk of Early Mortality in Patients with Newly Diagnosed Multiple Myeloma
    Liu, Chia-Jen
    Hsu, Pei
    Lin, Ting-Wei
    Gau, Jyh-Pyng
    Hsiao, Liang-Tsai
    Tzeng, Cheng-Hwai
    Chen, Po-Min
    Yu, Yuan-Bin
    Chiou, Tzeon-Jye
    Liu, Yao-Chung
    Liu, Jing-Hwang
    BLOOD, 2015, 126 (23)
12345